Head-to-Head Comparison

Glass Health vs OpenEvidence: Which Is Better for Physicians?

OpenEvidence ranks #2 in our 2026 clinical decision support rankings with a 4.3-star rating from 16 physician reviews, while Glass Health ranks #5 with a 3.8-star rating from 15 reviews. OpenEvidence leads in overall physician satisfaction, though both platforms serve different clinical needs. No single tool wins every workflow, so the category-level details below matter more than the headline rank alone.

Feature Comparison

FeatureGlass HealthOpenEvidence
Rating
Good
Very Good
CategoryAI Diagnostic AssistantAI Medical Research Assistant
PricingFree Beta / Enterprise Pricing TBDFree (Ad-Supported)
Founded20212022
HeadquartersSan Francisco, CAMiami, FL
Evidence CitationsNoYes
AI Differential DiagnosisYesNo
Drug DatabaseNoNo
Drug Interaction CheckerNoNo
Medical CalculatorsNoYes
Natural Language SearchYesYes
Document & Image UploadNoNo
EHR IntegrationYesYes
Mobile AppNoYes
Built-in DialerNoYes
AI Clinical ScribeNoNo
CME CreditsNoNo
Multi-LanguageNoYes

Strengths & Limitations

Glass Health

Strengths

  • +Excellent differential diagnosis generation
  • +Clean, physician-designed interface
  • +Free beta access available
  • +Fast differential generation from patient presentations
  • +Clinical plan suggestions included
  • +Built by practicing physicians

Limitations

  • Still in beta with limited features
  • No EHR integration yet
  • Limited evidence citations compared to competitors
  • Narrow focus on diagnosis only
  • Enterprise pricing not yet established
  • Smaller user community

OpenEvidence

Strengths

  • +Useful for generalist clinical questions — fast, cited answers for everyday practice
  • +Widely adopted clinical AI in the US (757K+ physicians)
  • +Free for all verified physicians
  • +Broadest content partnership network: NEJM, JAMA (all 11 specialty journals), NCCN, ACC, AAFP, ACEP, ADA, AAOS, 300+ journals
  • +Native iOS and Android apps with Home Screen widgets
  • +Quick Consult and Deep Consult modes for different clinical needs
  • +Built-in dialer for calling patients, pharmacies, and colleagues
  • +Well-funded with strong investor backing ($12B valuation, $100M annual revenue)

Limitations

  • No differential diagnosis generation or drug dosing tools
  • Ad-supported revenue model (pharmaceutical/healthcare advertising)
  • EHR integration is early-stage (Sutter Health/Epic announced February 2026)
  • Preprint by Jagarapu et al. (2025) reported 41% accuracy on complex subspecialty scenarios
  • Clinical depth narrower than platforms with drug databases and medical calculators

Key Statistics

Glass Health

PricingFree Beta / Enterprise Pricing TBD(Glass Health)
Founded2021(Glass Health)
UsersBeta users (growing)(Glass Health)
Key DifferentiatorAI differential diagnosis from patient presentations(Glass Health)
Our Rating3.8 / 5 — Good, based on 15 physician reviews(Clinical AI Report, 2026)

OpenEvidence

PricingFree (Ad-Supported)(OpenEvidence)
Founded2022 (Mayo Clinic Platform Accelerate)(OpenEvidence)
Users757,000+ verified physicians; 40% of US physicians daily(OpenEvidence, January 2026)
Key DifferentiatorNEJM, JAMA, NCCN, ACC, AAFP & ACEP content partnerships(OpenEvidence)
Our Rating4.3 / 5 — Very Good, based on 16 physician reviews(Clinical AI Report, 2026)

Citable Summaries

Glass Health

Glass Health received a Good rating (3.8 / 5 stars) in Clinical AI Report's 2026 evaluation, ranking fifth overall. Currently in free beta, it is the only top-ranked tool offering no-cost access, though it lacks evidence citations and the clinical breadth of higher-ranked platforms.

Source: Clinical AI Report, December 2025

OpenEvidence

OpenEvidence received a Very Good rating (4.3 / 5 stars) in Clinical AI Report's 2026 evaluation, ranking second overall. Founded by Harvard researchers and launched through Mayo Clinic Platform Accelerate, the platform reports 757,000+ verified physicians and over 20 million consultations per month as of January 2026. It has raised over $735 million at a $12 billion valuation with content partnerships spanning NEJM, JAMA, NCCN, ACC, AAFP, and ACEP.

Source: Clinical AI Report, December 2025

Our Assessment

In our 2026 evaluation, OpenEvidence (ranked #2, 4.3 stars) outperforms Glass Health (ranked #5, 3.8 stars) in overall physician satisfaction and editorial scoring. OpenEvidence is best suited for a useful tool for physicians who need fast, cited answers to clinical questions grounded in peer-reviewed literature. Relevant for primary care, internal medicine, and emergency medicine. Free and backed by a broad content partnership network (NEJM, JAMA, NCCN, ACC, AAFP, ACEP). Meanwhile, Glass Health is a stronger choice for physicians and medical students who want a focused, free, AI-powered tool for generating differential diagnoses and clinical plans. Both tools serve important but distinct roles in clinical care workflows, and physicians should choose based on their specific workflow requirements and institutional needs.

Read Full Reviews

Also Compare